IL318752A - Anti cancer combinations comprising targeted therapy - Google Patents
Anti cancer combinations comprising targeted therapyInfo
- Publication number
- IL318752A IL318752A IL318752A IL31875225A IL318752A IL 318752 A IL318752 A IL 318752A IL 318752 A IL318752 A IL 318752A IL 31875225 A IL31875225 A IL 31875225A IL 318752 A IL318752 A IL 318752A
- Authority
- IL
- Israel
- Prior art keywords
- targeted therapy
- anti cancer
- cancer combinations
- combinations
- targeted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22190139 | 2022-08-12 | ||
| PCT/EP2023/072324 WO2024033537A1 (en) | 2022-08-12 | 2023-08-11 | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318752A true IL318752A (en) | 2025-04-01 |
Family
ID=83080925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318752A IL318752A (en) | 2022-08-12 | 2023-08-11 | Anti cancer combinations comprising targeted therapy |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4568674A1 (en) |
| JP (1) | JP7733274B1 (en) |
| KR (1) | KR20250044876A (en) |
| CN (1) | CN119677517A (en) |
| AR (1) | AR130191A1 (en) |
| AU (1) | AU2023322689A1 (en) |
| CA (1) | CA3264277A1 (en) |
| CL (1) | CL2025000383A1 (en) |
| CO (1) | CO2025002794A2 (en) |
| IL (1) | IL318752A (en) |
| MX (1) | MX2025001671A (en) |
| TW (1) | TW202412809A (en) |
| WO (1) | WO2024033537A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3608317A1 (en) * | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| KR20250127179A (en) | 2014-04-14 | 2025-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | Imide-based modulators of proteolysis and associated methods of use |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JOP20190186A1 (en) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | Quinazoline compound |
| BR112020020307A2 (en) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE |
| AU2019307631A1 (en) | 2018-07-20 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via KEAP1 |
| JP2021176820A (en) * | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | Pharmaceutical composition comprising quinazoline compound as active ingredient |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| JP2023521698A (en) * | 2020-04-06 | 2023-05-25 | アルヴィナス・オペレーションズ・インコーポレイテッド | Compounds and methods for targeted degradation of KRAS |
| CN115836055A (en) * | 2020-06-30 | 2023-03-21 | 益方生物科技(上海)股份有限公司 | Quinazoline compounds, preparation method and application thereof |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| WO2022148422A1 (en) * | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| US20240092803A1 (en) * | 2021-01-08 | 2024-03-21 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| WO2022157629A1 (en) * | 2021-01-19 | 2022-07-28 | Lupin Limited | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer |
| PE20240235A1 (en) * | 2021-02-15 | 2024-02-16 | Astellas Pharma Inc | QUINAZOLINE COMPOUND TO INDUCE THE DEGRADATION OF THE KRAS MUTANT G12D PROTEIN |
| MX2023009520A (en) * | 2021-02-15 | 2023-08-24 | Astellas Pharma Inc | 4-aminoquinazoline compounds. |
| WO2023119677A1 (en) * | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
-
2023
- 2023-08-11 TW TW112130325A patent/TW202412809A/en unknown
- 2023-08-11 JP JP2025501550A patent/JP7733274B1/en active Active
- 2023-08-11 KR KR1020257004512A patent/KR20250044876A/en active Pending
- 2023-08-11 EP EP23757233.4A patent/EP4568674A1/en active Pending
- 2023-08-11 AU AU2023322689A patent/AU2023322689A1/en active Pending
- 2023-08-11 CA CA3264277A patent/CA3264277A1/en active Pending
- 2023-08-11 CN CN202380057900.7A patent/CN119677517A/en active Pending
- 2023-08-11 AR ARP230102132A patent/AR130191A1/en unknown
- 2023-08-11 WO PCT/EP2023/072324 patent/WO2024033537A1/en not_active Ceased
- 2023-08-11 IL IL318752A patent/IL318752A/en unknown
-
2025
- 2025-02-10 CL CL2025000383A patent/CL2025000383A1/en unknown
- 2025-02-10 MX MX2025001671A patent/MX2025001671A/en unknown
- 2025-03-05 CO CONC2025/0002794A patent/CO2025002794A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025001671A (en) | 2025-03-07 |
| EP4568674A1 (en) | 2025-06-18 |
| AU2023322689A1 (en) | 2025-03-20 |
| AR130191A1 (en) | 2024-11-13 |
| CO2025002794A2 (en) | 2025-03-27 |
| JP7733274B1 (en) | 2025-09-02 |
| CN119677517A (en) | 2025-03-21 |
| CL2025000383A1 (en) | 2025-04-11 |
| CA3264277A1 (en) | 2024-02-15 |
| JP2025530624A (en) | 2025-09-17 |
| KR20250044876A (en) | 2025-04-01 |
| TW202412809A (en) | 2024-04-01 |
| WO2024033537A1 (en) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202106392B (en) | Therapeutic rna for prostate cancer | |
| EP4010081A4 (en) | Combination therapy for treatment of cancer | |
| IL307964A (en) | Combination therapy for cancer treatment | |
| PT4225297T (en) | Combination therapy for treating cancer | |
| IL318752A (en) | Anti cancer combinations comprising targeted therapy | |
| IL300171A (en) | Combined therapy against cancer | |
| GB202301902D0 (en) | Combination therapy for cancer | |
| IL288178A (en) | Gmci and ddri combination therapy for treating cancer | |
| IL304436A (en) | Cancer therapy | |
| GB202218395D0 (en) | Cancer therapy | |
| IL316017A (en) | Combination therapy for treating cancer | |
| EP4251133C0 (en) | Combined therapy against cancer | |
| GB202001963D0 (en) | Cancer therapy | |
| AU2022903962A0 (en) | Targeted combination cancer therapy | |
| GB202318158D0 (en) | Cancer therapy | |
| GB202302018D0 (en) | Cancer therapy | |
| GB202212918D0 (en) | Cancer therapy | |
| GB202116680D0 (en) | Combination therapy for cancer | |
| HK40102590A (en) | Combination therapy for cancer treatment | |
| GB202208893D0 (en) | Combination therapy for cancer | |
| IL305777A (en) | Therapeutic combination for treating cancer | |
| GB202000984D0 (en) | Cancer therapy | |
| GB202103673D0 (en) | Combination therapy for cancer | |
| HK40107047A (en) | Therapeutic combination for treating cancer | |
| EP4313029A4 (en) | Combination therapy for cancer treatment |